Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Bendamustine with dexamethasone in R/R systemic AL amyloidosis

Raymond Comenzo • 20 Jul 2020
Amyloidosis Rare Diseases Antibodies Bendamustine Daratumumab Dexamethasone Ixazomib Lenalidomide Melphalan Prednisone

Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, outlines the use of bendamustine with dexamethasone, as an alternative, well-tolerated therapy in relapsed/refractory (R/R) systemic light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Raymond Comenzo

Main results from the ANDROMEDA study
2:54
Main results from the ANDROMEDA study
Raymond Comenzo • 1 Jun 2020
Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement
5:23
Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement
Raymond Comenzo • 1 Jun 2020
Amyloidosis: diagnosis and stem cell transplantation
13:14
Amyloidosis: diagnosis and stem cell transplantation
Raymond Comenzo • 14 Sep 2019
How will novel agents affect the amyloidosis population?
12:03
How will novel agents affect the amyloidosis population?
Raymond Comenzo • 14 Sep 2019

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Raymond Comenzo • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Raymond Comenzo • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Raymond Comenzo • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Raymond Comenzo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals